BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Wisconsin Cancer Collaborative - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Wisconsin Cancer Collaborative
X-ORIGINAL-URL:https://wicancer.org
X-WR-CALDESC:Events for Wisconsin Cancer Collaborative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20200308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20201101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20210314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20211107T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20220313T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20221106T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20211002T080000
DTEND;TZID=America/Chicago:20211002T170000
DTSTAMP:20260430T124347
CREATED:20210902T124914Z
LAST-MODIFIED:20210902T124914Z
UID:10438-1633161600-1633194000@wicancer.org
SUMMARY:Second Biennial Current Paradigms in Cardiovascular Care of the Cancer Patient/Survivor 2021: What Healthcare Professionals Should Know
DESCRIPTION:Program Information\nCardiovascular disease and cancer are the #1 and #2 causes of death in the United States. Both conditions involve many variables and their study is constant and diffuse. Cardio-oncology is a nascent field which focuses on preventing adverse cardiovascular outcomes in patients with active cancer; and improving the overall cardiovascular health of cancer survivors. This involves specific understanding of interactions between cancer and the cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including chemotherapy\, radiation therapy\, and newer targeted therapies which include immunotherapy\, such as immune checkpoint inhibitors and Car-T cell therapy. Furthermore\, recent developments in the medical management of cardiac disease (such as SGLT-2 inhibitors and ivabradine) present new therapeutic options for affected cancer patients and survivors. With such rapid change\, clinicians often find it difficult to remain up-to-date with the best means of identifying and treating patients. The purpose of this program is to familiarize primary care providers\, hospitalists\, oncologists\, cardiologists\, advanced practice providers\, pharmacists and trainees with updated treatment of cardiac conditions seen in cancer patients and survivors. \nTarget Audience \nThis activity has been planned for Primary Care Providers\, Hospitalists\, Oncologists\, Cardiologists\, Advanced Practice Providers\, Pharmacists\, Nurses and Medical Trainees interested in learning about the field of Cardio-Oncology. \nAccreditation / Designation \nIn support of improving patient care\, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. \nRush University Medical Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. \nRush University Medical Center designates this live activity for a maximum of 7.75 nursing contact hour(s). \nRush University Medical Center designates this knowledge-based live activity for a maximum of 7.75 contact hour(s) for pharmacists. \nEducational Goal  \nTo provide state-of-the art best practice information regarding the continuum of cardiac care for the oncology patient. \n\n\n\n\n\n\n\n\n\nLearning Objectives \nAt the conclusion of this activity\, participants should be better able to: \n1. Define the risks of cancer treatment-related cardiac dysfunction for patients who have undergone therapy for cancer. \n2. Provide some knowledge of cardiovascular effects of newer cancer therapies; as well as the potential use of newer cardiac drugs for management of cardiovascular complications associated with cancer\ntherapy. \n3. Implement strategies for early detection\, correction of cardiac risk factors and close\, as well as long-term cardiovascular monitoring in order to reduce the effects of cardiotoxicity (including arrhythmias\, heart failure\, severe hypertension\, valvular heart disease\, pericardial disease\, and\nautonomic dysfunction) for patients who are at risk for cancer treatment-related cardiac dysfunction. \n4. Assess appropriate and effective treatment strategies and referral for patients who have (or are at risk for) long-term toxicity-related cardiac\ndysfunction\, including heart failure\, valvular dysfunction\, hypertension\, and autonomic dysfunction. \n\n\n\n\n\n\n\n\n\n\n\n\nUnapproved Uses of Drugs/Devices \nIn accordance with requirements of the FDA\, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/ device for full prescribing/utilization information. \n  \nCurrent Paradigms in Cardiovascular Care of the Cancer Patient/Survivor: Midwest Regional Conference 2021 \nSaturday\, October 2\, 2021 \nConvene: 16 West Adams Street\, Chicago\, Illinois | Virtually Online
URL:https://wicancer.org/event/second-biennial-current-paradigms-in-cardiovascular-care-of-the-cancer-patient-survivor-2021-what-healthcare-professionals-should-know/
LOCATION:Webinar/Web Conference
END:VEVENT
END:VCALENDAR